Stallergenes adds France to roll-out of grass pollen therapy Oralair

France-based Stallergenes (GENP: FP) has announced the launch in France of Oralair, its grass pollen sublingual immunotherapy tablet, further to the publication of a Decree in the Official Journal on November 22.

The launch, which has taken place ahead of the 2013 pollen season, means that allergy specialists can avail of this medication which is indicated to treat allergic rhinitis to grass pollen, with or without conjunctivitis.

Oralair is the only tablet composed of five grass pollen extracts that correspond to the epidemiological exposure of patients and is administered under discontinuous protocol. After a 3-day titration phase, Oralair is administered for approximately 4 months before the pollen season and until the end of the latter. The treatment resumes the following year, adhering to the same schedule. Oralair has been granted a social security refund rate of 15%, acknowledging the fact that it provides an improvement in actual medical benefits (ASMR IV).